What are foreign giants accused of "demonstrating" to hoard goods?

On August 20th, the national collective procurement, known as the "College Entrance Examination" in the medical field, came to an end after a noisy day. Judging from the selection results, only two imported drugs were selected, and the rest were all out. Moreover, in the quotation, 15 drugs are overpriced, which does not show the sincerity of price reduction, and is even pointed out by the industry as a "demonstration".

For example, Merck gave up desloratadine oral sustained-release dosage forms at a price exceeding 1.56 times; Roche gave up the competition of capecitabine oral sustained-release dosage form by 2.23 times exceeding the price limit; Lilly gave up the competition of olanzapine orally disintegrating tablets by exceeding the price limit 1 times; What's more, GSK's lamivudine basically maintains the original price, exceeding the price limit by more than 80 times.

Judging from the rules of joint procurement release, this declared price is only valid if the declared price of the company is less than or equal to the highest effective declared price. This also means that the quotations of the above-mentioned multinational pharmaceutical companies are basically invalid.

A business person who participated in the on-site bidding said that the reason why foreign giants collectively gave up bidding may be that for them, the collected varieties are all original drugs with expired patents, which basically belong to their stock market. From the past experience, even if the price is reduced, the market profit will still be greatly reduced.

Extended data

Split has become the first choice for many foreign pharmaceutical companies.

This "abandoning the exam" Merck is the first foreign giant to announce the split plan this year. In February this year, Merck announced that it would start to divest its female health care products, mature products and biosimilars in 2020 and set up a new independent listed company. Merck will keep products with key growth points, such as tumors, vaccines, hospital products and animal health care.

GlaxoSmithKline also announced the split plan almost at the same time as Merck. On February 5th, GSK announced a two-year split plan, which will be split into two independent companies, one is a biopharmaceutical company focusing on the research and development of genes and new technologies in immune system-related scientific fields, and the other is a leading company in the field of consumer health care.

In fact, the split of GSK is a harbinger. 20 18, 18 In February, Pfizer and GlaxoSmithKline announced that they would merge their consumer health care businesses. At the same time, Emma Walmsley, CEO of GSK, also announced that after the merger of health care business, GSK will be divided into two parts, one is prescription drugs and vaccines, and the other is OTC products. The split announced this time is actually a continuation of 20 18, and it is clearer.

The two giants chose to spin off the original drug research business with expired patents, and both retained the tumor and immunity fields with broad market prospects in the future.